IL15 and cancer: A fusion between Pembrolizumab and IL-15 cytokine is deemed as a prominent anti-cancer molecule since Pembrolizumab mAb has shown clinical success in treating various cancers and a number of pre-clinical studies has underlined immunostimulatory effects of IL-15 cytokine [12, 33].